{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:21:32Z","timestamp":1790806892711,"version":"4.1.0"},"reference-count":26,"publisher":"SLACK, Inc.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmic Surg Lasers Imaging Retina"],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Objective:<\/jats:title>\n                    <jats:p>This study evaluated real-world treatment patterns and 1-year outcomes in patients with neovascular age-related macular degeneration (nAMD) initiating faricimab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>\n                      FARETINA-AMD was a retrospective study using data from the IRIS\n                      <jats:sup>\u00ae<\/jats:sup>\n                      Registry for patients diagnosed with nAMD initiating faricimab from February 2022 to March 2023.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Included in the study were 2,025 treatment-naive patients (2,184 eyes) and 22,253 patients (26,851 eyes) previously treated with anti-vascular endothelial growth factor (anti-VEGF) therapy. Visual acuity improved by 2.0 \u00b1 15.0 (mean \u00b1 SD) letters in treatment-naive eyes (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001) and was maintained in previously treated eyes at injection 7. Central subfield thickness (CST) improved by \u221253.1 \u00b1 64.8 \u03bcm in treatment-naive and \u221228.5 \u00b1 79.7 \u03bcm in previously treated eyes (both\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .0001); 78.4% and 66.8%, respectively, had achieved\/maintained C\n                      <jats:italic toggle=\"yes\">ST<\/jats:italic>\n                      \u2264 280 \u03bcm at injection 7. Dosing frequency was reduced in the second 6 months (mean 2.4\u20133.2 injections) versus the first 6 months (4.0\u20134.2) of treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Outcomes among patients with nAMD receiving faricimab over 1-year follow-up support the real-world effectiveness and extended durability of treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3928\/23258160-20260302-02","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:20:57Z","timestamp":1774621257000},"page":"242-250","source":"Crossref","is-referenced-by-count":2,"title":["One-year Real-world Outcomes With Faricimab in Neovascular Age-related Macular Degeneration"],"prefix":"10.3928","volume":"57","author":[{"given":"David C.","family":"Tabano","sequence":"first","affiliation":[{"name":"Genentech, South San Francisco, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferhina S.","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, New York Medical College, Valhalla, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Durga S.","family":"Borkar","sequence":"additional","affiliation":[{"name":"Duke University Eye Center, Durham, North Carolina;"},{"name":"Verana Health, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Leng","sequence":"additional","affiliation":[{"name":"Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Genentech, South San Francisco, California;"},{"name":"Verana Health, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Ko","sequence":"additional","affiliation":[{"name":"Genentech, South San Francisco, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alayna","family":"Myrick","sequence":"additional","affiliation":[{"name":"Verana Health, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Zwick","sequence":"additional","affiliation":[{"name":"Verana Health, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Downey","sequence":"additional","affiliation":[{"name":"Hoffmann-La Roche, Mississauga, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Barteselli","sequence":"additional","affiliation":[{"name":"Genentech, South San Francisco, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi P.","family":"Singh","sequence":"additional","affiliation":[{"name":"Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio;"},{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio and"},{"name":"Cleveland Clinic Martin Health, Cleveland Clinic Florida, Stuart, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2308","reference":[{"key":"e_1_3_2_2_2","unstructured":"Flaxel CJ Adelman RA Vemulakonda GA . Age-Related Macular Degeneration Preferred Practice Pattern 2019. American Academy of Ophthalmology. 2019."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005139.pub4"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305327"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-317337"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2015.06.023"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-024-03370-0"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-317434"},{"key":"e_1_3_2_9_2","volume-title":"Package insert","author":"Vabysmo","year":"2023","unstructured":"Vabysmo. Package insert. South San Francisco, CA: Genentech, Inc.; 2023."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00010-1"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.02.014"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-024-00525-9"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20250304-02"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181d87e04"},{"key":"e_1_3_2_15_2","volume-title":"Presented at the 24th EURETINA Congress","author":"Sheth V","unstructured":"Sheth V, Tabano D, Ali F, . 12-month real-world clinical and anatomical outcomes with faricimab in patients with diabetic macular edema: the FARETINA-DME Study. Presented at the 24th EURETINA Congress; September 19\u201322, 2024; Barcelona, Spain."},{"issue":"7","key":"e_1_3_2_16_2","first-page":"2113","article-title":"Real-world clinical and anatomical outcomes in patients with neovascular age-related macular degeneration (nAMD) treated with faricimab: The FARETINAAMD study","volume":"65","author":"Tabano D","year":"2024","unstructured":"Tabano D, Ko S, Borkar D, Leng T, Ali F, Shaia JK, Myers R, LaPrise A, Singh RP. Real-world clinical and anatomical outcomes in patients with neovascular age-related macular degeneration (nAMD) treated with faricimab: The FARETINAAMD study. Invest. Ophthalmol. Vis. Sci. 2024;65(7):2113.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-024-03218-7"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02553-5"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2024.07.020"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S409822"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-024-03110-4"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-025-01108-z"},{"issue":"7","key":"e_1_3_2_23_2","first-page":"4905","article-title":"Real-world treatment patterns and outcomes in the first 6 and 12 months of faricimab use among eyes with neovascular age-related macular degeneration (nAMD) in the UK: FARWIDE-nAMD","volume":"65","author":"Varma D","year":"2024","unstructured":"Varma D, Talks J, de Salvo G, . Real-world treatment patterns and outcomes in the first 6 and 12 months of faricimab use among eyes with neovascular age-related macular degeneration (nAMD) in the UK: FARWIDE-nAMD. Invest Ophthalmol Vis Sci. 2024;65(7):4905. https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2798432","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2023.10.018"},{"key":"e_1_3_2_25_2","unstructured":"A real-world study to gain clinical insights into Roche ophthalmology products (VOYAGER). ID: NCT05476926. ClinicalTrials.gov. Updated December 22 2025. Accessed March 10 2026. https:\/\/www.clinicaltrials.gov\/study\/NCT05476926"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100442"},{"key":"e_1_3_2_27_2","volume-title":"Presented at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Congress","author":"Guymer R","unstructured":"Guymer R; VOYAGER Investigators. VOYAGER Study: update on faricimab in the real world. Presented at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Congress; February 3, 2024."}],"container-title":["Ophthalmic Surgery, Lasers and Imaging Retina"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T18:53:27Z","timestamp":1784573607000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/23258160-20260302-02"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"alternative-id":["10.3928\/23258160-20260302-02"],"URL":"https:\/\/doi.org\/10.3928\/23258160-20260302-02","relation":{},"ISSN":["2325-8160","2325-8179"],"issn-type":[{"value":"2325-8160","type":"print"},{"value":"2325-8179","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}